Skip to main content
Top
Published in: Intensive Care Medicine 3/2017

01-03-2017 | Editorial

Should all septic patients be given systemic anticoagulation? No

Authors: Tom van der Poll, Steven M. Opal

Published in: Intensive Care Medicine | Issue 3/2017

Login to get access

Excerpt

According to current guidelines [1], all patients who are admitted to the intensive care unit (ICU) with sepsis/septic shock should receive some form of anticoagulant prophylaxis to decrease the risk of deep venous thrombosis and venous thromboembolism (VTE). This VTE prophylaxis usually comes in the form of low dose, systemic anticoagulation to prevent new thrombus formation. Such a dosing strategy is generally applied with unfractionated or low molecular weight heparin, supplemented with venous intermittent compression devices when feasible, or replaced by injectable direct thrombin inhibitors if heparin-induced thrombocytopenia develops. A new generation of oral direct inhibitors of factor Xa or thrombin are now available as VTE preventive agents [2]. Experience of these agents in septic patients is limited and will need to be carefully studied to determine if they could be a new alternative to existing methods of coagulation inhibition. Low dose heparin is intended to prevent new thrombus formation without necessarily clearing existing intravascular clots. High dose therapeutic levels of heparin are needed to clear thrombi but add an attendant risk of causing excess bleeding. …
Literature
1.
go back to reference Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2012) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228CrossRef Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2012) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228CrossRef
2.
3.
4.
go back to reference Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055–2064CrossRefPubMed Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366(22):2055–2064CrossRefPubMed
5.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709CrossRefPubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709CrossRefPubMed
6.
go back to reference Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238–247CrossRefPubMed Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238–247CrossRefPubMed
7.
go back to reference Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15):1869–1878CrossRefPubMed Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15):1869–1878CrossRefPubMed
8.
go back to reference Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and the risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126–2134. doi:10.1007/s00134-013-3111-9 CrossRefPubMed Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and the risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126–2134. doi:10.​1007/​s00134-013-3111-9 CrossRefPubMed
9.
go back to reference Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12):862–874CrossRefPubMedPubMedCentral Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12):862–874CrossRefPubMedPubMedCentral
10.
go back to reference van der Poll T, Herwald H (2014) The coagulation system and its function in early immune defense. Thromb Haemost 112(4):640–648CrossRefPubMed van der Poll T, Herwald H (2014) The coagulation system and its function in early immune defense. Thromb Haemost 112(4):640–648CrossRefPubMed
11.
go back to reference Vincent JL (2003) Nosocomial infections in adult intensive-care units. Lancet 361(9374):2068–2077CrossRefPubMed Vincent JL (2003) Nosocomial infections in adult intensive-care units. Lancet 361(9374):2068–2077CrossRefPubMed
12.
go back to reference van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, van der Poll T, MARS Consortium (2016) Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315(14):1469–1479CrossRefPubMed van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, van der Poll T, MARS Consortium (2016) Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315(14):1469–1479CrossRefPubMed
13.
go back to reference Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13(1):34–45CrossRefPubMed Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13(1):34–45CrossRefPubMed
14.
go back to reference Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102(9):3085–3092CrossRefPubMed Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102(9):3085–3092CrossRefPubMed
15.
go back to reference Levi M, Schouten M, van’t Veer C, van der Poll T (2011) Factor V Leiden mutation in severe infection and sepsis. Semin Thromb Hemost 37(8):955–960CrossRefPubMed Levi M, Schouten M, van’t Veer C, van der Poll T (2011) Factor V Leiden mutation in severe infection and sepsis. Semin Thromb Hemost 37(8):955–960CrossRefPubMed
Metadata
Title
Should all septic patients be given systemic anticoagulation? No
Authors
Tom van der Poll
Steven M. Opal
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 3/2017
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4607-x

Other articles of this Issue 3/2017

Intensive Care Medicine 3/2017 Go to the issue

Imaging in Intensive Care Medicine

Bilateral adrenal hemorrhage